4Doherty J, Kamae I, Lee K, et al. What is next for pharmacoeconomics and outcomes research in Asia[J] . Value in Health, 2004, 7(2): 118. 被引量：1
5Briggs AH, O' Brien BJ. The death of cost -minimization analysis[J] .Health Econ, 2001, 10(2): 179. 被引量：1
6Woo J, Cockram C. Cost estimates for chronic diseases [J ]. Dis Manage Health Outcomes, 2000, 8(1) : 29. 被引量：1
7Drummond M, Sculpher M, Common methodological flaws in economic evaluations[J] .Medical Care, 2005, 43(7 Suppl) : 5. 被引量：1
8Guidelines for the economic evaluation of health technologies. Canada 3rd Edition [S] . Ottawa. Canadian Agency for Drugs and Technologies in Health, 2006. 被引量：1
9Buxton MJ. Economic evaluation and decision making in the UK[J] .Pharmacoeconomics, 2006, 24(11) : 1 133. 被引量：1
